Showing results (121-130 of 281) with videos related to

Sort By:
Pageof 29
Applied and Environmental Microbiology|February 7, 2001
Characterization and pathogenic potential of Listeria monocytogenes isolates from the smoked fish industryD M Norton, J M Scarlett, K Horton, et al.
Cell Research|January 2, 2008
XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaksJulie K Horton, Mary Watson, Donna F Stefanick, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|June 28, 2014
"Choosing wisely" in an academic department of medicineJonas Z Hines, Justin L Sewell, Niraj L Sehgal, et al.
Molecular Cancer Research : MCR|April 29, 2014
Base excision repair defects invoke hypersensitivity to PARP inhibitionJulie K Horton, Donna F Stefanick, Rajendra Prasad, et al.
Practical Radiation Oncology|March 4, 2015
Exercise behavior and patient-reported outcomes in women with early breast cancer receiving locoregional radiation therapyRitu Arya, Sharareh Siamakpour-Reihani, Manisha Palta, et al.
Pediatrics|February 9, 2011
Impact of prenatal exposure to piperonyl butoxide and permethrin on 36-month neurodevelopmentMegan K Horton, Andrew Rundle, David E Camann, et al.
The Journal of Biological Chemistry|May 8, 2001
Photoaffinity labeling of mouse fibroblast enzymes by a base excision repair intermediate. Evidence for the role of poly(ADP-ribose) polymerase-1 in DNA repairO I Lavrik, R Prasad, R W Sobol, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|February 1, 2014
Dosimetric comparison of 3D conformal, IMRT, and V-MAT techniques for accelerated partial-breast irradiation (APBI)Jian-Jian Qiu, Zheng Chang, Janet K Horton, et al.
International Journal of Radiation Oncology, Biology, Physics|June 30, 2009
Radiosensitization of chemotherapy-refractory, locally advanced or locally recurrent breast cancer with trastuzumab: a phase II trialJanet K Horton, Jan Halle, Madlyn Ferraro, et al.
American Journal of Hypertension|July 1, 1988
Terazosin, a new selective alpha 1-adrenergic blocking agent. Results of long-term treatment in patients with essential hypertensionR R Luther, H N Glassman, C B Estep, et al.
Pageof 29